{
    "code": "52026216",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52026216",
    "time": "2021-06-11 03:17:43",
    "許可證字號": "衛部藥輸字第026216號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "113\/03\/18",
    "發證日期": "103\/03\/18",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA05202621602",
    "中文品名": "貝坦利持續性藥效錠50毫克",
    "英文品名": "Betmiga Prolonged-release Tablets 50mg",
    "適應症": "單一治療：治療伴有急尿、頻尿和\/或急迫性尿失禁症狀的膀胱過動症。\r\n與蕈毒鹼性拮抗劑併用：與蕈毒鹼性拮抗劑solifenacin succinate併用可用於治療伴有急尿、頻尿和\/或急迫性尿失禁症狀的膀胱過動症。",
    "劑型": "121持續性藥效錠",
    "包裝": "2-1000錠鋁箔盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "108\/03\/18",
    "主成分略述": "Mirabegron",
    "限制項目": "02輸　入",
    "申請商名稱": "620110R660  台灣安斯泰來製藥股份有限公司",
    "申請商地址": "台北市中山區民生東路３段１０號５樓",
    "主製造廠": [
        {
            "製造廠名稱": "FUS0472000  AVARA PHARMACEUTICAL TECHNOLOGIES, INC.",
            "製造廠廠址": "3300 MARSHALL AVE. NORMAN, OK 73072 USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FJP9414000  ASTELLAS PHARMA TECH CO., LTD. TAKAHAGI TECHNOLOGY CENTER",
            "製造廠廠址": "160-2, AKAHARNA, TAKAHAGI-SHI, IBARAKI 318-0001, JAPAN",
            "製造廠公司地址": "",
            "製造廠國別": "JAPAN",
            "製程": "原料藥製造廠"
        },
        {
            "製造廠名稱": "FNL0047000  ASTELLAS PHARMA EUROPE B.V.",
            "製造廠廠址": "HOGEMAAT 2, 7942 JG MEPPEL, THE NETHERLANDS",
            "製造廠公司地址": "SYLVIUSWEG 62, 2333 BE LEIDEN, THE NETHERLANDS.",
            "製造廠國別": "NETHERLANDS",
            "製程": "包裝"
        }
    ],
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200080700",
            "成分名稱": "Mirabegron",
            "含量描述": "",
            "含量": "50.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "黃色",
        "特殊氣味": "",
        "刻痕": "無",
        "形狀": "橢圓形",
        "標記一": "355",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "貝坦利持續性藥效錠50mg正反面鋁箔片 (BET50-B1408-02)-107-03-09(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026216&Seq=003&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "BET-I2002-08-109-08-20.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026216&Seq=009&Type=9"
        },
        {
            "title": "BET50-C1803-04-110-02-04.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026216&Seq=007&Type=8"
        },
        {
            "title": "BET50-B2012-04-110-02-04.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026216&Seq=006&Type=8"
        }
    ]
}